View post:
CymaBay Appoints Thomas Wiggans and Janet Dorling to Board of Directors
Related Post
- Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance... - March 26th, 2024
- GTG Global Collaborations and Innovation Update - March 26th, 2024
- Phathom Pharmaceuticals Launches Direct-to-Consumer Campaign, “VOQUEZNA Can Kick Some Acid” - March 26th, 2024
- Reviva to Present RECOVER Phase 3 Clinical Trial Data for Brilaroxazine in Schizophrenia at the ASCPT 2024 Annual Meeting - March 26th, 2024
- Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares - March 26th, 2024
- Essential Pharma and AcedrA Biopharmaceuticals sign Distribution Agreement to commercialize essential medicines in the Middle East and North Africa... - March 26th, 2024
- Third Harmonic Bio Announces Fourth Quarter and Full Year 2023 Financial Results - March 26th, 2024
- Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC - March 26th, 2024
- Yield10 Bioscience Announces that the Plant Biosafety Office of the Canadian Food Inspection Agency has Cleared Genome-edited E3902 Camelina for... - March 26th, 2024
- Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines - March 26th, 2024
- Shockwave Medical to Participate in the 23rd Annual Needham Virtual Healthcare Conference - March 26th, 2024
- Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint... - March 26th, 2024
- Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications - March 26th, 2024
- ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M - March 26th, 2024
- PharmAla Biotech Signs Sale Agreement with Numinus - March 26th, 2024
- Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024 - March 26th, 2024
- AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast - March 26th, 2024
- Celularity Receives Healthcare Common Procedure Coding System (HCPCS) Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for... - March 26th, 2024
- Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund - March 26th, 2024
- Better Choice Company Initiates Legal Action Against Alphia, a Portfolio Company of Private Equity Firm PAI - March 26th, 2024
- Precision Neuroscience Expands Clinical Research In Brain–Computer Interface - March 24th, 2024
- Telomir Pharmaceuticals Releases New Pre-Clinical Data for Telomir-1 to Be Presented at the Global Longevity Federation Conference in Las Vegas on... - March 24th, 2024
- Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Expanded Use Access Program Achieve Complete... - March 24th, 2024
- Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights - March 24th, 2024
- Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19 - March 24th, 2024
- Theratechnologies Announces Update on its Preclinical Oncology Research Program - March 24th, 2024
- Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results - March 24th, 2024
- Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial - March 24th, 2024
- Salarius Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update - March 24th, 2024
- Veru Reschedules Annual Meeting of Shareholders - March 24th, 2024
- Alvotech Announces Increase in Number of Own Shares - March 24th, 2024
- Nutra Pharma Corp. Reaches Settlement with SEC - March 24th, 2024
- IBEX Reports Results for the Second Quarter and Six Months Ended January 31, 2024 - March 24th, 2024
- AgeX Therapeutics Reports Fourth Quarter and Annual 2023 Financial Results - March 24th, 2024
- In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy,... - March 24th, 2024
- UCB Convening Notice to the General Meeting of the Shareholders 2024 - March 22nd, 2024
- Idorsia thanks Guy Braunstein for his years of service as he retires - March 22nd, 2024
- Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria - March 22nd, 2024
- Nicox's Shareholder Letter - March 22nd, 2024
- First patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis - March 22nd, 2024
- Press Release: Availability of the Q1 2024 Memorandum for modelling purposes - March 22nd, 2024
- Change in Orion Group Executive Management Board: change in Orion's group-level functions - March 22nd, 2024
- The change negotiations concerning Orion’s Kuopio plant have been concluded – the company has decided to continue to explore the outsourcing of... - March 22nd, 2024
- Pharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for... - March 22nd, 2024
- Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards - March 22nd, 2024
- Humacyte Fourth Quarter and Year End 2023 Financial Results and Business Update - March 22nd, 2024
- OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain... - March 22nd, 2024
- HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights - March 22nd, 2024
- NMD Pharma Receives FDA IND Clearance to initiate a Phase 2b Clinical Trial of NMD670 in Generalized Myasthenia Gravis Patients in the US - March 22nd, 2024
- Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium - March 22nd, 2024
- Novartis Fabhalta® (iptacopan) receives positive CHMP opinion as first oral monotherapy for adult patients with paroxysmal nocturnal hemoglobinuria... - March 22nd, 2024
- Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results - March 22nd, 2024
- Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD - March 22nd, 2024
- Recce Pharmaceuticals Announces RECCE® Trademark Registered in Canada, Strengthening Global IP Portfolio - March 22nd, 2024
- Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan - March 22nd, 2024
- Achieve Life Sciences Announces Data from Cytisinicline ORCA Program to be Presented at the 2024 Society for Research on Nicotine and Tobacco (SRNT)... - March 20th, 2024
- Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome - March 20th, 2024
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 20th, 2024
- Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Friday, March 22, 2024 - March 20th, 2024
- Kane Biotech Extends Exclusivity Period on its Offer for its Interest in STEM Animal Health - March 20th, 2024
- Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments - March 20th, 2024
- RespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to... - March 20th, 2024
- Eko2o S.A.S., a Majority-Controlled Subsidiary of MedCana/SFWJ, Sets Sights on Expansion Into Costa Rica and Central America - March 20th, 2024
- TFF Pharmaceuticals Announces Update on Clinical Programs - March 20th, 2024
- Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating... - March 20th, 2024
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment - March 20th, 2024
- Celularity Submits Request to U.S. FDA for Orphan Drug Designation for PDA-002 Asset Treating Facioscapulohumeral Muscular Dystrophy - March 20th, 2024
- Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial - March 20th, 2024
- Nurix Presents the Discovery and Chemical Structure of First-in-Class CBL-B Inhibitor NX-1607 at the American Chemical Society (ACS) Meeting - March 20th, 2024
- Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office - March 20th, 2024
- XTL To Aquire The Social Proxy - March 20th, 2024
- Decisions taken by Orion Corporation’s Annual General Meeting on 20 March 2024 - March 20th, 2024
- Orion Corporation: Organising meeting of the Board of Directors - March 20th, 2024
- Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for... - March 20th, 2024
- Zealand Pharma's Annual General Meeting 2024 - March 20th, 2024
- Novonesis will host a conference call regarding 2024 outlook and 2023 pro forma financials on March 21 - March 18th, 2024
- TaiMed Biologics and AcedrA BioPharmaceuticals Partner to Commercialize Trogarzo® (Ibalizumab-uiyk) in the Middle East and North Africa Region - March 18th, 2024
- RS BioTherapeutics Selected for Presentation at American Thoracic Society’s 2024 Respiratory Innovation Summit - March 18th, 2024
- Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset... - March 18th, 2024
- Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics... - March 18th, 2024
Recent Comments